-
1.发明专利Thymidine kinase mutant and fusion protein having thymidine kinase and guanylate kinase activities 审中-公开具有酪氨酸激酶和谷氨酸激酶活性的酪氨酸激酶突变体和融合蛋白
公开(公告)号：JP2012115270A
公开(公告)日：2012-06-21
申请号：JP2012000673
申请日：2012-01-05
发明人： BLACK MARGARET E
IPC分类号： C12N15/09 , A61K31/7088 , A61K31/711 , A61K31/713 , A61K35/76 , A61K38/00 , A61K38/45 , A61K45/00 , A61K48/00 , A61K49/00 , A61K51/00 , A61P7/04 , A61P11/00 , A61P25/28 , A61P31/00 , A61P31/04 , A61P31/12 , A61P31/16 , A61P31/18 , A61P31/20 , A61P33/00 , A61P35/00 , A61P35/02 , A61P37/00 , A61P37/08 , A61P43/00 , C12N5/10 , C12N9/12 , C12Q1/16
CPC分类号： C12N9/503 , A61K38/00 , A61K48/00 , C07K2319/00 , C12N9/1211 , C12N9/1229 , C12N2799/022 , C12N2799/028
摘要： PROBLEM TO BE SOLVED: To provide new thymidine kinase mutants and TK fusion proteins with enhanced biological activities which are suitable for a variety of applications (for example, gene therapy), and to provide other related advantages.SOLUTION: The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties.
摘要翻译： 要解决的问题：提供新的胸苷激酶突变体和TK融合蛋白，其具有适合于各种应用（例如，基因治疗）的增强的生物活性，并提供其他相关优点。 解决方案：本发明提供编码疱疹病毒科胸苷激酶的分离的核酸分子，其包含一个或多个突变，编码从DRH核苷结合位点朝向N末端的氨基酸取代中的至少一个突变增加 与未突变的胸苷激酶相比，胸苷激酶的生物学活性。 与未突变的胸苷激酶相比，这种突变包括Q基质结合结构域内的氨基酸取代，其增加胸苷激酶的生物学活性。 在另一方面，提供了具有鸟苷酸激酶和胸苷激酶生物学性质的融合蛋白。 版权所有（C）2012，JPO＆INPIT
-
2.发明专利Thymidine kinase mutant and fusion protein having thymidine kinase and guanylate kinase activity 有权具有酪氨酸激酶和谷氨酸激酶活性的酪氨酸激酶突变体和融合蛋白
公开(公告)号：JP2008301828A
公开(公告)日：2008-12-18
申请号：JP2008176378
申请日：2008-07-04
发明人： BLACK MARGARET E
IPC分类号： C12N15/09 , A61K31/513 , A61K31/522 , A61K31/7068 , A61K31/7072 , A61K31/711 , A61K35/76 , A61K38/00 , A61K38/45 , A61K48/00 , A61K49/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P37/06 , C12N5/10 , C12N9/12
CPC分类号： C12N9/503 , A61K38/00 , A61K48/00 , C07K2319/00 , C12N9/1211 , C12N9/1229 , C12N2799/022 , C12N2799/028
摘要： PROBLEM TO BE SOLVED: To provide new thymidine kinase mutants and TK (thymidine kinase) fusion proteins with properly increased biological activity for various applications (for example, gene therapy), and other related merits. SOLUTION: The present invention provides isolated nucleic acid molecules encoding a Herpesviridae thymidine kinase enzyme comprising one or more mutations, at least one of the mutations encoding an amino acid substitution located toward the N-terminus from a DRH nucleoside binding site which increases a biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Such mutations include amino acid substitutions within a Q substrate binding domain which increases biological activity of the thymidine kinase, as compared to unmutated thymidine kinase. Within a further aspect, fusion proteins are provided which have both guanylate kinase and thymidine kinase biological properties. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译： 要解决的问题：提供新的胸苷激酶突变体和TK（胸苷激酶）融合蛋白，具有适当增加的各种应用的生物活性（例如基因治疗）和其他相关优点。 解决方案：本发明提供编码疱疹病毒科胸苷激酶的分离的核酸分子，其包含一个或多个突变，编码从DRH核苷结合位点向N末端位置氨基酸取代中的至少一个突变增加 与未突变的胸苷激酶相比，胸苷激酶的生物学活性。 与未突变的胸苷激酶相比，这种突变包括增加胸苷激酶生物学活性的Q底物结合结构域内的氨基酸取代。 在另一方面，提供了具有鸟苷酸激酶和胸苷激酶生物学性质的融合蛋白。 版权所有（C）2009，JPO＆INPIT
-
搜索结果
2 条记录 (耗时 0.023 秒)
